The National Association of Community Health Centers (NACHC) strongly urged the U.S. Health and Human Services Secretary Xavier Becerra yesterday “to swiftly impose” fines on drug manufacturers that restrict shipments of 340B-purchased drugs to contract pharmacies and “hold
…
Phase 2 of the debate over huge cuts in 340B hospitals’ Medicare Part B drug reimbursement is gearing up. It will be played out in a federal appeals court in Washington, D.C., a federal district court in Washington, and the pages
…
Six U.S. House members—three Democrats and three Republicans—are urging fellow representatives to sign a letter asking U.S. Health and Human Services (HHS) Department leaders “to begin enforcement actions against pharmaceutical companies that refuse to honor 340B discounts on
…
The U.S. Supreme Court ruled unanimously this morning that the federal government unlawfully slashed Medicare Part B drug reimbursement for many 340B hospitals by almost 30 percent during 2018 and 2019.
The National Association of Community Health Centers “would love to see” Congress pass legislation by the end of this year that stops drug makers from restricting 340B contract pharmacy arrangements and stops pharmacy benefit managers from taking covered
…
With more than six months to go in the year, the number of refunds that drug manufacturers have had to provide to 340B providers has already topped the previous annual record of 17. Drug manufacturer Novo Nordisk becomes
…
The U.S. Health Resources and Services Administration (HRSA) is seeking comment on plans to revise online forms covered entities must fill out when they enroll in the 340B program, recertify their eligibility annually, or update information in 340B
…
Drug manufacturers Novartis and United Therapeutics (UT) last night urged a federal appeals court in Washington, D.C., to affirm a lower court’s November 2021 judgement that the 340B statute does not stop manufacturers from attaching any conditions to
…
Seven U.S. representatives—five Democrats and two Republicans—lauded the 340B program on the House floor Tuesday night during an hour of speeches organized by Rep. Abigail Spanberger (D-Va.) and co-hosted by Rep. John Rose (R-Tenn.).
Just months after deadlocking, the U.S. Federal Trade Commission on Tuesday voted unanimously on Tuesday to launch an investigation into pharmacy benefit managers’ business practices to assess their impact on prescription drug access and affordability.
*Sign up for news summaries and alerts from 340B Report
